ArchiMed takes biopharma firm Esperion Therapeutics private for $1.1bn
Esperion focuses on bringing cardiometabolic and rare/orphan disease therapies to market.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
